What Supernus Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 20 |
| Total trades | 10 | 98 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 35,999 | 329,294 |
| Disposed | 15,564 | 265,675 |
| Net activity | +20,435 | +63,619 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Dec Timothy C | Senior Vice-President & CFO | Aug 12 | Withheld — tax / exercise cost · F | −604 | $46.57 | −$28.1K | 9,129 |
| Dec Timothy C | Senior Vice-President & CFO | Aug 12 | Exercise / conversion · M | +1,250 | — | — | 9,733 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Aug 12 | Withheld — tax / exercise cost · F | −1,158 | $46.57 | −$53.9K | 18,637 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Aug 12 | Exercise / conversion · M | +2,500 | — | — | 19,795 |
| Khattar Jack A. | President, CEO | Aug 12 | Withheld — tax / exercise cost · F | −12,642 | $46.57 | −$589K | 1,258,351 |
| Khattar Jack A. | President, CEO | Aug 12 | Exercise / conversion · M | +29,849 | — | — | 1,270,993 |
| Rubin Jonathan | SVP, Chief Medical Officer | Aug 12 | Withheld — tax / exercise cost · F | −363 | $46.57 | −$16.9K | 13,979 |
| Rubin Jonathan | SVP, Chief Medical Officer | Aug 12 | Exercise / conversion · M | +750 | — | — | 14,342 |
| Mottola Frank | SVP, Chief Tech. Ops. Officer | Aug 12 | Withheld — tax / exercise cost · F | −797 | $46.57 | −$37.1K | 19,544 |
| Mottola Frank | SVP, Chief Tech. Ops. Officer | Aug 12 | Exercise / conversion · M | +1,650 | — | — | 20,341 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 18 | Open-market sale · S | −412 | $50.48 | −$20.8K | 17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 18 | Open-market sale · S | −6,838 | $49.55 | −$339K | 17,456 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 18 | Exercise / conversion · M | +7,250 | $39.40 | +$286K | 24,294 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 17 | Open-market sale · S | −22,290 | $50.73 | −$1.13M | 17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 17 | Open-market sale · S | −27,710 | $49.95 | −$1.38M | 39,334 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 17 | Exercise / conversion · M | +15,000 | $38.60 | +$579K | 67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 17 | Exercise / conversion · M | +12,250 | $36.75 | +$450K | 52,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 17 | Exercise / conversion · M | +22,750 | $39.40 | +$896K | 39,794 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 16 | Open-market sale · S | −15,886 | $50.49 | −$802K | 17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 16 | Open-market sale · S | −34,114 | $50.18 | −$1.71M | 32,930 |
Loading...
